분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2015-01-08 01:40:07 , Hit : 1664
 US pharmacy deals could cut costs of AbbVie and Gilead's HCV treatments

http://www.in-pharmatechnologist.com/Hot-Topics/Lifecycle-management/Gilead-strikes-back-at-AbbVie-with-exclusive-payer-deal-for-hep-C-drug

By Dan Stanton+

06-Jan-2015
Last updated on 06-Jan-2015 at 15:29 GMT


AbbVie and Gilead have both signed exclusive deals with Pharmacy Benefit Managers for their HCV treatments
AbbVie and Gilead have both signed exclusive deals with Pharmacy Benefit Managers for their HCV treatments


Related tags: Inhibitor, Viekira Pak, Harvoni, Sovaldi, HCV, Olysio, Hepatitis C, AbbVie, Gilead, J&J, Janssen, Express Scripts, CVS

Related topics: Lifecycle management, Drug Delivery, APIs (active pharmaceutical ingredients), Delivery formulations



Gilead and AbbVie’s exclusive deals with payers CVS and Express Scripts could help cut the cost of the new class of treatments for America’s three million Hepatitis C sufferers.



Related news:

Hep C biocatalyst sales slump as Codexis feels Sovaldi impact

Indian drugmakers to bring cheap HCV drug Sovaldi to developing world

Abbvie: Sligo expansion about more than just Hep C candidate

US FDA approves Gilead's $1,125 a pill combination Hep C drug

Generic Sovaldi makers could pocket upwards of $600m says analyst




A number of new drugs for the estimated 3.2 million people in the US living with chronic Hepatitis C virus infection have been launched over the past year, with Abbvie’s drug, Viekira Pak, the latest following its approval by the US Food and Drug Administration (FDA) last month.

The drug combines three active pharmaceutical ingredients (API): an NS5A inhibitor, ombitasvir; NS3/4A protease inhibitor, paritaprevir; and non-nucleoside NS5B polymerase inhibitor, ritonavir.

The triple-action mechanism goes further than Gilead’s two HCV treatments launched in the last year:

Sovaldi (sofosbuvir), a nucleotide analog that inhibits the polymerase enzyme that the hepatitis C virus uses to replicate its RNA, and Harvoni, a combination of sofosbuvir and the drug ledipasvir, which inhibits the viral phosphoprotein, NS5A, involved in viral replication, assembly, and secretion.

These drugs, along with J&J’s Olysio approved in November 2013, can be taken without the need for co-administration of interferon and offer sufferers heightened cure rates with fewer side effects than conventional treatments. Furthermore, the oral delivery method improves patient adherence and compliance.

The impact of these new treatments has already affected sales of other hepatitis C drugs, such as Merck & Co.’s Victrelis - approved for use in combination with peginterferon alfa and ribavirin – which had Q3 2014 sales of $27m , 78% less than the same period 2013.



Similarly, Codexis, which supplies intermediates and biocatalysts for hepatitis C drugs including Victrelis, blamed a 60% drop in sales last August on the impact of Sovaldi.

Price Battle?

However, the benefits of these new drugs come at a cost and Gilead has been hit with criticism regarding its pricing, $84,000 for a 12-week course of Sovaldi , equating to $1,000 a pill, with Harvoni costing even more .

While Viekira Pak has been similarly priced ($83,319), within days of approval AbbVie signed a deal with Express Scripts, the largest Pharmacy Benefit Manager (PBM) in the US, to supply the drug exclusively to HCV sufferers enrolled through its healthcare plan.

ISI analyst Mark Schoenebaum said such a deal coupled with a number of “basically interchangeable” drugs in an “intensively competitive” sector could start a price war between AbbVie and Gilead.

Despite this, he told in-Pharmatechnologist.com the discount AbbVie had offered to gain access with Express Scripts was most likely less than 30% and would only have a “modest” impact on Gilead’s US business.

But yesterday, in what fellow ISI analyst Ross Muken described as “unsurprising but timely,” Gilead announced it too had struck an exclusive deal with the PBM CVS for Harvoni/Sovaldi to be given preferred formulary status.

Describing Gilead’s offerings as more attractive due to the potentially shorter regimen, more convenient dosing, and less drug-to-drug interaction issues, Muken added CVS was likely able to “garner an attractive discount for its members.”

In the UK, the cost of a 12-week course of Sovaldi is £34,983 ($53,155) while in 91 developing countries, a course of the drug will be available for a cost as low as $300 thanks to a tech transfer deal Gilead recently signed with seven Indian generic drugmakers.


Copyright - Unless otherwise stated all contents of this web site are © 2015 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions







  US pharmacy deals could cut costs of AbbVie and Gilead's HCV treatments  이성욱 2015/01/08 1664
1006   Janssen, Isis Pharma Ink Up-to-$835M Antisense Agreement  이성욱 2015/01/07 1181
1005   CVS Gives Preferred Status to Gilead’s Hepatitis C Drugs  이성욱 2015/01/07 1304
1004   Mass. developer of messenger RNA drugs gets $450M funding boost  이성욱 2015/01/07 966
1003   아직도 풀리지 않은 STAP줄기세포 미스터리  이성욱 2015/01/06 1009
1002   에볼라 확산원인에 대한 새로운 주장  이성욱 2015/01/06 1114
1001   Scientists explain how stem cells and 'bad luck' cause cancer  이성욱 2015/01/06 926
1000   자가 항체에 의한 전신 홍반성 루프스 발생 기작  이성욱 2015/01/05 1551
999   줄기세포로 만든 초기 난자와 정자  이성욱 2014/12/31 1147
998   텔로머레이즈 기반 유전자 요법으로 심장마비 치료  이성욱 2014/12/24 1664
997   일본의 검증팀 STAP 세포 재현 포기, 오보카타 사임  이성욱 2014/12/23 1075
996   아수라장 속에서 탄생한 생명  이성욱 2014/12/17 1237
995   암 생존율을 높일 수 있는 면역세포  이성욱 2014/12/16 1091
994   FDA approves 9-valent HPV vaccine for certain cancers  이성욱 2014/12/12 1142
993   C형 간염 치료에서 비용 효율성을 보인 시메프레비르(simeprevir) 기반 요법  이성욱 2014/12/11 1713
992   Y 염색체 상실을 초래할 수 있는 흡연  이성욱 2014/12/10 1341
991   술의 역사: 영장류가 진화한 것은 알코올 섭취능력 때문?  이성욱 2014/12/04 1267
990   혈우병 환자들에게 안전성과 효과를 입증한 유전자 요법  이성욱 2014/11/27 1615
989   EMA panel recommends approval of DAA regimen for patients with HCV  이성욱 2014/11/26 1282
988   AMD를 치료하는데 사용될 수 있는 HIV/AIDS 약물들  이성욱 2014/11/26 1393

[이전 10개] [1]..[11][12][13] 14 [15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN